Eltrombopag is a thrombopoietin receptor agonist used to treat thrombocytopenia or aplastic anemia associated with various etiologies. Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough.
- Mechanism
- Curator reviewed
Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor. Eltrombopag is a stimulator of STAT and JAK phosphorylation. Unlike recombinant TPO or romiplostim, Eltrombopag does not activate the AKT pathway in any way. It should be noted that when given to patients with aplastic anemia, other lineages besides platelet count were increased, suggesting that either eltrombopag enhanced the effect of TPO in vivo; or there is a yet uncovered mechanism of action at work.
- Primary indication
- Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow.Curator reviewed · 5 structured indications
- Formula / weight
- C25H22N4O4 · 442.4666 g/mol (avg)
- First approval
- Canada, 2015 · United States, 2008 · European Union, 2021
- Code names
- ETB115 · SB-497115
- Brand names
Resolves to
XDXWLKQMMKQXPV-QYQHSDTDSA-NSMILESCC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC=CC(=C2)C(O)=O)=C1O)C1=CC=C(C)C(C)=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Eltrombopag, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account